Source: Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences, Inc.
(NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that
develops and markets unique and effective solutions for the treatment of
dermatological conditions and advanced tissue care, today announced
that the company’s Microcyn®-based antimicrobial wound solution and
wound hydrogel dressing have received Class IIb medical device
registrations from the Australian Government Department of Health as
well as Class IIb registrations from the New Zealand Medicines and
Medical Devices Safety Authority.
The registrations, similar
in substance, provide for the Microdacyn60® wound care products to be
used in the debridement and moistening of chronic wounds, ulcers, cuts,
abrasions and burns including those located in any human cavity such as
the oral, nasal and ear. By reducing the microbial load via a local
antimicrobial effect, these products assist in creating a moist
environment, enabling the body to perform in its own healing process.
“Australia
and New Zealand are two of the more challenging countries in terms of
securing medical device registration,” said Bruce Thornton, Oculus VP
for international marketing/sales. “They set the bar high relative to
validating both product safety and efficacy. For that reason, we
recognize these registrations as continued substantiation of the
Microcyn Technology’s unparalleled performance in the treatment of
wounds, rashes and skin infections. With these two new registrations in
hand, the Microcyn Technology is now approved in over 45 countries
worldwide.”
For the next four months, the Microdacyn60 products
will be in pre-marketing mode with various sampling programs deployed
for healthcare professionals in both countries. The planned commercial
launch is scheduled for January 2017 with the Microcyn-based products
being distributed exclusively by Oculus’ Australian/New Zealand partner,
Te Arai Biofarma Limited.
About Oculus Innovative Sciences, Inc.
Oculus
Innovative Sciences is a specialty pharmaceutical company that develops
and markets unique and effective solutions for the treatment of
dermatological conditions and advanced tissue care. The company’s
products, which are sold throughout the United States and
internationally, have improved outcomes for more than five million
patients globally by reducing infections, itch, pain, scarring and
harmful inflammatory responses. The company's headquarters are in
Petaluma, California, with manufacturing operations in the United States
and Latin America. European marketing and sales are headquartered in
Roermond, Netherlands. More information can be found at www.oculusis.com.
No comments:
Post a Comment